Medical device developer Altaviz has announced the launch of a new auto-injector platform, AltaVISC, for drug delivery.
The new platform utilises Pico-Cylinders, developed by Altaviz’s affiliate company Picocy, to enable the delivery of both high-volume and high-viscosity therapies.
Go deeper with GlobalData
AltaVISC can be tailored to administer a wide array of drug formulations, including shear-sensitive molecules and high-viscosity biologics.
It retains its form factor while offering an extensive pressure range, enabling precise control over factors like temperature and gas composition in both human and environmental settings.
The AltaVISC gas drive system facilitates impact-free delivery. It also helps maintain environmental sustainability using atmospheric gases and reduced material needs.
See Also:
Altaviz co-CEO Jack Auld said: “As we developed this platform, we were hyper-focused on creating technology that leapfrogs the current state of the art.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“With pharmaceutical companies heading towards large-molecule, protein-based treatments while taking more large-volume therapies from the clinic into the home, we knew that we had to create a platform that combines the capacity to deliver the most demanding applications with the ease to dial back to any application.”
Established in 2012 by a team of medical design engineers, Altaviz is focused on the design and manufacturing of medical devices to address the challenges and meet the objectives of surgeons, clinicians and patient customers.
The company’s customers range from startups to major medical device and pharma companies.
